CORONA Remedies Limited: Trading Window Closure for Q2 FY27 Financial Results
CORONA Remedies Limited will close its trading window from October 01, 2026, until 48 hours after the declaration of Q2 FY27 financial results. The board meeting date for approving these results will be announced later.
The closure of the trading window is a standard compliance procedure and does not directly impact the company's operations or financial performance. It primarily affects insider trading activities.
The announcement is a routine regulatory disclosure regarding the closure of the trading window, which is standard practice before financial results are announced. It does not contain any positive or negative financial information.
CORONA Remedies Limited has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct.
The trading window will be effective from October 01, 2026, and will remain closed until 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending on September 30, 2026.
The date of the Board Meeting to consider these financial results will be communicated separately in due course.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under trading window disclosure. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.